These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 10703829)
41. Renal-dose dopamine: will the message now get through? Galley HF Lancet; 2000 Dec 23-30; 356(9248):2112-3. PubMed ID: 11191531 [No Abstract] [Full Text] [Related]
42. The renal response to an acute protein load in man: clinical perspective. Rodríguez-Iturbe B Nephrol Dial Transplant; 1990; 5(1):1-9. PubMed ID: 2109280 [No Abstract] [Full Text] [Related]
49. Can the effects of protein restriction on the progression of renal failure also be achieved by pharmacological means? Verberckmoes R; Van Renterghem Y Blood Purif; 1989; 7(1):58-60. PubMed ID: 2493259 [TBL] [Abstract][Full Text] [Related]
50. Renal side-effects of cyclo-oxygenase-type-2 inhibitor use. Stubanus M; Riegger GA; Kammerl MC; Fischereder M; Krämer BK Lancet; 2000 Feb; 355(9205):753. PubMed ID: 10703829 [No Abstract] [Full Text] [Related]
51. Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation. Knight S; Johns EJ Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):11-6. PubMed ID: 18047621 [TBL] [Abstract][Full Text] [Related]
52. Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. LeLorier J; Bombardier C; Burgess E; Moist L; Wright N; Cartier P; Huckell V; Hunt R; Nawar T; Tobe S Can J Cardiol; 2002 Dec; 18(12):1301-8. PubMed ID: 12518182 [TBL] [Abstract][Full Text] [Related]
53. Cutaneous vasculitis induced by cyclo-oxygenase-2 selective inhibitors. Drago F; Brusati C; Desirello G; Cacciapuoti M; Rebora A J Am Acad Dermatol; 2004 Dec; 51(6):1029-30. PubMed ID: 15583611 [No Abstract] [Full Text] [Related]
54. Renal effects of cyclo-oxygenase-type-2 inhibition. Krämer BK Lancet; 2000 Jan; 355(9199):236-7. PubMed ID: 10675151 [No Abstract] [Full Text] [Related]
55. COX-1 sparing and COX-2 inhibitory drugs: the renal and hepatic safety and tolerability profiles of celecoxib. Whelton A Am J Ther; 2000 May; 7(3):151-2. PubMed ID: 11317163 [No Abstract] [Full Text] [Related]